Cargando…

Pediatric Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Clinical Presentation, Infectivity, and Immune Responses

OBJECTIVES: As schools plan for re-opening, understanding the potential role children play in the coronavirus infectious disease 2019 (COVID-19) pandemic and the factors that drive severe illness in children is critical. STUDY DESIGN: Children ages 0-22 years with suspected severe acute respiratory...

Descripción completa

Detalles Bibliográficos
Autores principales: Yonker, Lael M., Neilan, Anne M., Bartsch, Yannic, Patel, Ankit B., Regan, James, Arya, Puneeta, Gootkind, Elizabeth, Park, Grace, Hardcastle, Margot, St. John, Anita, Appleman, Lori, Chiu, Michelle L., Fialkowski, Allison, De la Flor, Denis, Lima, Rosiane, Bordt, Evan A., Yockey, Laura J., D'Avino, Paolo, Fischinger, Stephanie, Shui, Jessica E., Lerou, Paul H., Bonventre, Joseph V., Yu, Xu G., Ryan, Edward T., Bassett, Ingrid V., Irimia, Daniel, Edlow, Andrea G., Alter, Galit, Li, Jonathan Z., Fasano, Alessio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7438214/
https://www.ncbi.nlm.nih.gov/pubmed/32827525
http://dx.doi.org/10.1016/j.jpeds.2020.08.037
_version_ 1783572759398318080
author Yonker, Lael M.
Neilan, Anne M.
Bartsch, Yannic
Patel, Ankit B.
Regan, James
Arya, Puneeta
Gootkind, Elizabeth
Park, Grace
Hardcastle, Margot
St. John, Anita
Appleman, Lori
Chiu, Michelle L.
Fialkowski, Allison
De la Flor, Denis
Lima, Rosiane
Bordt, Evan A.
Yockey, Laura J.
D'Avino, Paolo
Fischinger, Stephanie
Shui, Jessica E.
Lerou, Paul H.
Bonventre, Joseph V.
Yu, Xu G.
Ryan, Edward T.
Bassett, Ingrid V.
Irimia, Daniel
Edlow, Andrea G.
Alter, Galit
Li, Jonathan Z.
Fasano, Alessio
author_facet Yonker, Lael M.
Neilan, Anne M.
Bartsch, Yannic
Patel, Ankit B.
Regan, James
Arya, Puneeta
Gootkind, Elizabeth
Park, Grace
Hardcastle, Margot
St. John, Anita
Appleman, Lori
Chiu, Michelle L.
Fialkowski, Allison
De la Flor, Denis
Lima, Rosiane
Bordt, Evan A.
Yockey, Laura J.
D'Avino, Paolo
Fischinger, Stephanie
Shui, Jessica E.
Lerou, Paul H.
Bonventre, Joseph V.
Yu, Xu G.
Ryan, Edward T.
Bassett, Ingrid V.
Irimia, Daniel
Edlow, Andrea G.
Alter, Galit
Li, Jonathan Z.
Fasano, Alessio
author_sort Yonker, Lael M.
collection PubMed
description OBJECTIVES: As schools plan for re-opening, understanding the potential role children play in the coronavirus infectious disease 2019 (COVID-19) pandemic and the factors that drive severe illness in children is critical. STUDY DESIGN: Children ages 0-22 years with suspected severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection presenting to urgent care clinics or being hospitalized for confirmed/suspected SARS-CoV-2 infection or multisystem inflammatory syndrome in children (MIS-C) at Massachusetts General Hospital were offered enrollment in the Massachusetts General Hospital Pediatric COVID-19 Biorepository. Enrolled children provided nasopharyngeal, oropharyngeal, and/or blood specimens. SARS-CoV-2 viral load, ACE2 RNA levels, and serology for SARS-CoV-2 were quantified. RESULTS: A total of 192 children (mean age, 10.2 ± 7.0 years) were enrolled. Forty-nine children (26%) were diagnosed with acute SARS-CoV-2 infection; an additional 18 children (9%) met the criteria for MIS-C. Only 25 children (51%) with acute SARS-CoV-2 infection presented with fever; symptoms of SARS-CoV-2 infection, if present, were nonspecific. Nasopharyngeal viral load was highest in children in the first 2 days of symptoms, significantly higher than hospitalized adults with severe disease (P = .002). Age did not impact viral load, but younger children had lower angiotensin-converting enzyme 2 expression (P = .004). Immunoglobulin M (IgM) and Immunoglobulin G (IgG) to the receptor binding domain of the SARS-CoV-2 spike protein were increased in severe MIS-C (P < .001), with dysregulated humoral responses observed. CONCLUSIONS: This study reveals that children may be a potential source of contagion in the SARS-CoV-2 pandemic despite having milder disease or a lack of symptoms; immune dysregulation is implicated in severe postinfectious MIS-C.
format Online
Article
Text
id pubmed-7438214
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-74382142020-08-20 Pediatric Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Clinical Presentation, Infectivity, and Immune Responses Yonker, Lael M. Neilan, Anne M. Bartsch, Yannic Patel, Ankit B. Regan, James Arya, Puneeta Gootkind, Elizabeth Park, Grace Hardcastle, Margot St. John, Anita Appleman, Lori Chiu, Michelle L. Fialkowski, Allison De la Flor, Denis Lima, Rosiane Bordt, Evan A. Yockey, Laura J. D'Avino, Paolo Fischinger, Stephanie Shui, Jessica E. Lerou, Paul H. Bonventre, Joseph V. Yu, Xu G. Ryan, Edward T. Bassett, Ingrid V. Irimia, Daniel Edlow, Andrea G. Alter, Galit Li, Jonathan Z. Fasano, Alessio J Pediatr Original Article OBJECTIVES: As schools plan for re-opening, understanding the potential role children play in the coronavirus infectious disease 2019 (COVID-19) pandemic and the factors that drive severe illness in children is critical. STUDY DESIGN: Children ages 0-22 years with suspected severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection presenting to urgent care clinics or being hospitalized for confirmed/suspected SARS-CoV-2 infection or multisystem inflammatory syndrome in children (MIS-C) at Massachusetts General Hospital were offered enrollment in the Massachusetts General Hospital Pediatric COVID-19 Biorepository. Enrolled children provided nasopharyngeal, oropharyngeal, and/or blood specimens. SARS-CoV-2 viral load, ACE2 RNA levels, and serology for SARS-CoV-2 were quantified. RESULTS: A total of 192 children (mean age, 10.2 ± 7.0 years) were enrolled. Forty-nine children (26%) were diagnosed with acute SARS-CoV-2 infection; an additional 18 children (9%) met the criteria for MIS-C. Only 25 children (51%) with acute SARS-CoV-2 infection presented with fever; symptoms of SARS-CoV-2 infection, if present, were nonspecific. Nasopharyngeal viral load was highest in children in the first 2 days of symptoms, significantly higher than hospitalized adults with severe disease (P = .002). Age did not impact viral load, but younger children had lower angiotensin-converting enzyme 2 expression (P = .004). Immunoglobulin M (IgM) and Immunoglobulin G (IgG) to the receptor binding domain of the SARS-CoV-2 spike protein were increased in severe MIS-C (P < .001), with dysregulated humoral responses observed. CONCLUSIONS: This study reveals that children may be a potential source of contagion in the SARS-CoV-2 pandemic despite having milder disease or a lack of symptoms; immune dysregulation is implicated in severe postinfectious MIS-C. Elsevier Inc. 2020-12 2020-08-20 /pmc/articles/PMC7438214/ /pubmed/32827525 http://dx.doi.org/10.1016/j.jpeds.2020.08.037 Text en © 2020 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Original Article
Yonker, Lael M.
Neilan, Anne M.
Bartsch, Yannic
Patel, Ankit B.
Regan, James
Arya, Puneeta
Gootkind, Elizabeth
Park, Grace
Hardcastle, Margot
St. John, Anita
Appleman, Lori
Chiu, Michelle L.
Fialkowski, Allison
De la Flor, Denis
Lima, Rosiane
Bordt, Evan A.
Yockey, Laura J.
D'Avino, Paolo
Fischinger, Stephanie
Shui, Jessica E.
Lerou, Paul H.
Bonventre, Joseph V.
Yu, Xu G.
Ryan, Edward T.
Bassett, Ingrid V.
Irimia, Daniel
Edlow, Andrea G.
Alter, Galit
Li, Jonathan Z.
Fasano, Alessio
Pediatric Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Clinical Presentation, Infectivity, and Immune Responses
title Pediatric Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Clinical Presentation, Infectivity, and Immune Responses
title_full Pediatric Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Clinical Presentation, Infectivity, and Immune Responses
title_fullStr Pediatric Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Clinical Presentation, Infectivity, and Immune Responses
title_full_unstemmed Pediatric Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Clinical Presentation, Infectivity, and Immune Responses
title_short Pediatric Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Clinical Presentation, Infectivity, and Immune Responses
title_sort pediatric severe acute respiratory syndrome coronavirus 2 (sars-cov-2): clinical presentation, infectivity, and immune responses
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7438214/
https://www.ncbi.nlm.nih.gov/pubmed/32827525
http://dx.doi.org/10.1016/j.jpeds.2020.08.037
work_keys_str_mv AT yonkerlaelm pediatricsevereacuterespiratorysyndromecoronavirus2sarscov2clinicalpresentationinfectivityandimmuneresponses
AT neilanannem pediatricsevereacuterespiratorysyndromecoronavirus2sarscov2clinicalpresentationinfectivityandimmuneresponses
AT bartschyannic pediatricsevereacuterespiratorysyndromecoronavirus2sarscov2clinicalpresentationinfectivityandimmuneresponses
AT patelankitb pediatricsevereacuterespiratorysyndromecoronavirus2sarscov2clinicalpresentationinfectivityandimmuneresponses
AT reganjames pediatricsevereacuterespiratorysyndromecoronavirus2sarscov2clinicalpresentationinfectivityandimmuneresponses
AT aryapuneeta pediatricsevereacuterespiratorysyndromecoronavirus2sarscov2clinicalpresentationinfectivityandimmuneresponses
AT gootkindelizabeth pediatricsevereacuterespiratorysyndromecoronavirus2sarscov2clinicalpresentationinfectivityandimmuneresponses
AT parkgrace pediatricsevereacuterespiratorysyndromecoronavirus2sarscov2clinicalpresentationinfectivityandimmuneresponses
AT hardcastlemargot pediatricsevereacuterespiratorysyndromecoronavirus2sarscov2clinicalpresentationinfectivityandimmuneresponses
AT stjohnanita pediatricsevereacuterespiratorysyndromecoronavirus2sarscov2clinicalpresentationinfectivityandimmuneresponses
AT applemanlori pediatricsevereacuterespiratorysyndromecoronavirus2sarscov2clinicalpresentationinfectivityandimmuneresponses
AT chiumichellel pediatricsevereacuterespiratorysyndromecoronavirus2sarscov2clinicalpresentationinfectivityandimmuneresponses
AT fialkowskiallison pediatricsevereacuterespiratorysyndromecoronavirus2sarscov2clinicalpresentationinfectivityandimmuneresponses
AT delaflordenis pediatricsevereacuterespiratorysyndromecoronavirus2sarscov2clinicalpresentationinfectivityandimmuneresponses
AT limarosiane pediatricsevereacuterespiratorysyndromecoronavirus2sarscov2clinicalpresentationinfectivityandimmuneresponses
AT bordtevana pediatricsevereacuterespiratorysyndromecoronavirus2sarscov2clinicalpresentationinfectivityandimmuneresponses
AT yockeylauraj pediatricsevereacuterespiratorysyndromecoronavirus2sarscov2clinicalpresentationinfectivityandimmuneresponses
AT davinopaolo pediatricsevereacuterespiratorysyndromecoronavirus2sarscov2clinicalpresentationinfectivityandimmuneresponses
AT fischingerstephanie pediatricsevereacuterespiratorysyndromecoronavirus2sarscov2clinicalpresentationinfectivityandimmuneresponses
AT shuijessicae pediatricsevereacuterespiratorysyndromecoronavirus2sarscov2clinicalpresentationinfectivityandimmuneresponses
AT leroupaulh pediatricsevereacuterespiratorysyndromecoronavirus2sarscov2clinicalpresentationinfectivityandimmuneresponses
AT bonventrejosephv pediatricsevereacuterespiratorysyndromecoronavirus2sarscov2clinicalpresentationinfectivityandimmuneresponses
AT yuxug pediatricsevereacuterespiratorysyndromecoronavirus2sarscov2clinicalpresentationinfectivityandimmuneresponses
AT ryanedwardt pediatricsevereacuterespiratorysyndromecoronavirus2sarscov2clinicalpresentationinfectivityandimmuneresponses
AT bassettingridv pediatricsevereacuterespiratorysyndromecoronavirus2sarscov2clinicalpresentationinfectivityandimmuneresponses
AT irimiadaniel pediatricsevereacuterespiratorysyndromecoronavirus2sarscov2clinicalpresentationinfectivityandimmuneresponses
AT edlowandreag pediatricsevereacuterespiratorysyndromecoronavirus2sarscov2clinicalpresentationinfectivityandimmuneresponses
AT altergalit pediatricsevereacuterespiratorysyndromecoronavirus2sarscov2clinicalpresentationinfectivityandimmuneresponses
AT lijonathanz pediatricsevereacuterespiratorysyndromecoronavirus2sarscov2clinicalpresentationinfectivityandimmuneresponses
AT fasanoalessio pediatricsevereacuterespiratorysyndromecoronavirus2sarscov2clinicalpresentationinfectivityandimmuneresponses